Monte Rosa Therapeutics amends Form 144 reporting RSU activity

Monte Rosa Therapeutics amended a Form 144 filing reporting restricted stock unit activity tied to compensation and subsequent sales by a reporting holder.

Rhea-AI Filing Summary

Monte Rosa Therapeutics amended a Form 144 filing reporting restricted stock unit activity tied to compensation and subsequent sales by a reporting holder. The amendment lists 21,865 RSUs awarded on 01/02/2025 with a vesting/exercise-related date of 01/02/2026. The filing records dispositions by Markus Warmuth on 03/02/2026 and 04/14/2026 with reported transaction amounts of $97,974.22 and $141,124.80 respectively. The submission is an amended (144/A) notice dated 05/01/2026.

Insights

Securities Compliance Attorney

Amendment documents RSU award and resale notices under Form 144/A.

The amendment lists a 21,865 RSU award dated 01/02/2025 and identifies sales by a reporting holder on 03/02/2026 and 04/14/2026 with amounts of $97,974.22 and $141,124.80. This filing updates prior sale notices; it does not by itself state method of sale or purchaser.

Timing and mechanics of any resale (brokered block, private sale, or otherwise) are not described in the excerpt; subsequent filings or broker confirmations would specify execution details.

Corporate Governance Analyst

The disclosure shows compensation-related equity and insider dispositions, administrative in nature.

The record shows RSUs granted as Stock Award with a compensation purpose and two monetary disposition entries tied to Markus Warmuth. The amendment format suggests clerical or timing corrections rather than a new strategic action.

Investors seeking further context should consult transfer/transaction-level filings for method and whether proceeds went to the selling holder or issuer; that treatment is not included in the excerpt.

Key Figures

RSUs awarded: 21,865 shares Award-related date: 01/02/2026 Disposition amount: $97,974.22 +2 more

5 metrics

RSUs awarded 21,865 shares Stock Award dated 01/02/2025

Award-related date 01/02/2026 Date associated with RSU award in filing

Disposition amount $97,974.22 Recorded on 03/02/2026

Disposition amount $141,124.80 Recorded on 04/14/2026

Filing amendment date 05/01/2026 Form 144/A amendment date

Key Terms

RSU, Stock Award, Form 144/A

3 terms

RSU financial

"RSU | 01/02/2025 | Stock Award"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

Stock Award financial

"RSU | 01/02/2025 | Stock Award | From Issuer"

Form 144/A regulatory

"144/A: Filer Information"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Monte Rosa Therapeutics' 144/A amendment disclose?

It amends a Form 144 to report equity award and resale details. The amendment lists 21,865 RSUs awarded on 01/02/2025 and sale activity recorded on 03/02/2026 and 04/14/2026.

How many RSUs are shown in the filing for GLUE?

The filing shows 21,865 restricted stock units tied to a Stock Award dated 01/02/2025 with an associated date of 01/02/2026 in the excerpt.

What monetary amounts are reported in the 144/A amendment?

Two transaction amounts are listed: $97,974.22 linked to 03/02/2026 and $141,124.80 linked to 04/14/2026 in the provided excerpt.

Who is the reporting holder named in the amendment?

The amendment names Markus Warmuth with an address at 321 Harrison Ave, Suite 900, Boston MA 02118 as the individual associated with the reported dispositions on the listed dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 09:22 AM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK	0001855643
Filer CCC	XXXXXXXX
Previous Accession Number Of The Filing	0001965301-26-000046
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer	Monte Rosa Therapeutics, Inc.
SEC File Number	001-40522
Address of Issuer	321 HARRISON AVENUE SUITE 900 BOSTON MASSACHUSETTS 02118
Phone	617-949-2643
Name of Person for Whose Account the Securities are To Be Sold	Warmuth Markus
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Capital Management 500 Boylston Street Suite 1300 Boston MA 02116	5467	103446.63	84382573	05/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
RSU	01/02/2025	Stock Award	From Issuer			21865	01/02/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Markus Warmuth 321 Harrison Ave, Suite 900 Boston MA 02118	Monte Rosa Therapeutics Inc	03/02/2026	5466	97974.22
Markus Warmuth 321 Harrison Ave, Suite 900 Boston MA 02118	Monte Rosa Therapeutics Inc	04/14/2026	8000	141124.80

144/A: Remarks and Signature

Remarks
Date of Notice	06/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Carmen Zamores as a duly authorized representative of National Financial Services LLC, as attorney-in-fact for Warmuth Markus
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)